| Trial ID: | L1339 |
| Source ID: | NCT00999037
|
| Associated Drug: |
Sevelamer Carbonate
|
| Title: |
FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00999037/results
|
| Conditions: |
Secondary Hyperparathyroidism
|
| Interventions: |
DRUG: Sevelamer Carbonate|OTHER: Placebo
|
| Outcome Measures: |
Primary: Change in FGF-23 Level, Change in FGF23 value from baseline in response to Renvela at 12 weeks in comparison to placebo., 12 weeks | Secondary: 1,25(OH)2vitamin D Value, Percentage change in 1,25(OH)2vitamin D level from baseline at 12 weeks., 12 week|Serum Phosphate Concentration, Change in serum phosphate at 12 weeks from baseline, 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: University of California, Los Angeles | Collaborators: Loma Linda University
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT
|
| Phases: |
|
| Enrollment: |
18
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION
|
| Start Date: |
2009-10
|
| Completion Date: |
2015-06
|
| Results First Posted: |
2017-03-31
|
| Last Update Posted: |
2023-05-31
|
| Locations: |
UCLA, Los Angeles, California, 90095, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00999037
|
